Last reviewed · How we verify
SAGE-547
SAGE-547 is an intravenous formulation of an antisense oligonucleotide that targets the GABA_A receptor alpha 1 subunit.
SAGE-547 is an intravenous formulation of an antisense oligonucleotide that targets the GABA_A receptor alpha 1 subunit. Used for Status epilepticus.
At a glance
| Generic name | SAGE-547 |
|---|---|
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Drug class | antisense oligonucleotide |
| Target | GABA_A receptor alpha 1 subunit |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By binding to the GABA_A receptor alpha 1 subunit, SAGE-547 aims to increase the expression of the alpha 1 subunit, which can help to reduce seizure activity. This is particularly relevant for the treatment of status epilepticus, a severe and life-threatening form of epilepsy. The antisense oligonucleotide mechanism allows for a targeted and specific approach to modulating the GABA_A receptor, which can help to reduce the risk of adverse effects.
Approved indications
- Status epilepticus
Common side effects
- Hypotension
- Bradycardia
- Respiratory depression
Key clinical trials
- A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD (PHASE3)
- Study on Allopregnanolone and Depression in Perimenopausal Women (PHASE4)
- Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD. (PHASE2)
- National Pregnancy Registry for Psychiatric Medications
- A Study With SAGE-547 for Super-Refractory Status Epilepticus (PHASE3)
- A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B) (PHASE3)
- Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder (PHASE1)
- A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAGE-547 CI brief — competitive landscape report
- SAGE-547 updates RSS · CI watch RSS
- Supernus Pharmaceuticals, Inc. portfolio CI